12
Participants
Start Date
August 31, 2003
Primary Completion Date
August 31, 2008
Study Completion Date
September 30, 2008
IL2
Interleukin-2 will be given at a starting dose of 7 MU/m2/day by subcutaneous injection days 1-5, on weeks 1 through 3, in four week (28 days) cycles.
Zoledronic acid
Zoledronic acid will be given on day 1 intravenously over 15 or 30 minutes starting at 400mcg. If no significant increase in gamma delta-T cell augmentation is seen, the dose of zoledronic acid will be increased in the subsequent cycle up to a maximum dose of 3mg.
University of Wisconsin, Madison
Collaborators (1)
Novartis
INDUSTRY
University of Wisconsin, Madison
OTHER